Methods and compositions for treating breast cancer with dendritic cell vaccines

Patent metadata

Field	Value
Publication number	US-10023841-B2
Application number	US-201514719968-A
Country	US
Kind code	B2
Filing date	May 22, 2015
Priority date	May 23, 2014
Publication date	Jul 17, 2018
Grant date	Jul 17, 2018

Abstract

Disclosed are compositions and methods for treatment of breast cancer. Disclosed methods and compositions include dendritic cells loaded with cyclin B1 and WT-1 peptide antigens for immunotherapy. These dendritic cell vaccines are administered alone or in combination with other cancer therapies to improve outcomes. Disclosed methods also involve the use of therapeutic agents, such as anakinra, that block the IL-1 inflammation pathway. These agents are used in combination with chemotherapy and/or immunotherapy in treating breast cancer.

First claim

The invention claimed is:

1. A pharmaceutical composition comprising
isolated, active dendritic cells displaying cyclin B1 peptide epitopes; and
isolated, active dendritic cells displaying WT-1 peptide epitopes,
wherein the isolated, active dendritic cells displaying WT-1 peptide epitopes have been incubated with WT-1 peptide antigens comprising SEQ ID NOs:3-8,
and wherein the isolated, active dendritic cells displaying the cyclin B1 peptide epitopes and the isolated, active dendritic cells displaying the WT-1 peptide epitopes have been incubated with peptide antigens comprising SEQ ID NOs:9-40.

2. A method of making active, antigen-loaded dendritic cells for treating breast cancer in a subject comprising:
isolating monocytes from the subject's blood;
differentiating the isolated monocytes into dendritic cells;
incubating the dendritic cells with one or more isolated cyclin B1 peptide antigens and WT-1 peptide antigens, wherein the one or more isolated WT-1 peptide antigens comprise SEQ ID NOs:3-8;
incubating the dendritic cells with peptide antigens comprising SEQ ID NOs:9-40; and
activating the dendritic cells.

3. A method of treating breast cancer in a subject comprising:
isolating monocytes from the subject's blood;
differentiating the monocytes to form dendritic cells;
incubating the dendritic cells with an antigenic composition comprising (i) one or more isolated cyclin B1 peptide antigens and WT-1 peptide antigens, (ii) one or more dendritic cell activating agents, and (iii) peptide antigens comprising SEQ ID NOs:9-40 to form activated, antigen-loaded dendritic cells; and
administering to the subject a first pharmaceutical composition comprising the activated, antigen-loaded dendritic cells;
wherein the one or more isolated WT-1 peptide antigens comprise SEQ ID NOs:3-8.

4. The method of claim 3 , wherein the one or more isolated cyclin B1 peptide antigens comprise SEQ ID NO:1 and/or SEQ ID NO:2.

5. The method of claim 3 , wherein the step of differentiating the isolated monocytes is performed by incubating the isolated monocytes with IFNα and GM-CSF.

6. The method of claim 3 , wherein the one or more dendritic cell activating agents comprise lipopolysaccharide, CD40 ligand, and CL075.

7. The method of claim 3 , wherein the subject has been diagnosed with triple negative breast cancer.

8. The method of claim 3 , wherein the subject has previously been administered chemotherapy and the chemotherapy did not result in a pathologic complete response in the subject.

9. The method of claim 3 , wherein the breast cancer has been determined to be resistant to chemotherapy.

10. The method of claim 3 , further comprising administering to the subject an IL-1R antagonist.

11. The method of claim 10 , wherein the IL-1R antagonist is anakinra.

12. The method of claim 3 , wherein the concentration of the active, antigen-loaded dendritic cells in the first pharmaceutical composition is between about 1×10 6 and 15×10 6 viable cells/ml.

13. The method of claim 3 , wherein the concentration of the active, antigen-loaded dendritic cells in the first pharmaceutical composition is at least about 15×10 6 viable cells/ml.

14. The method of claim 3 , wherein the first pharmaceutical composition is administered to the subject in combination with one or more chemotherapeutic agents comprising one or more of doxorubicin, cyclophosphamide, and paclitaxel.

15. The method of claim 3 , wherein the first pharmaceutical composition is administered to the subject intratumorally.

16. The method of claim 15 , further comprising administering to the subject a second pharmaceutical composition comprising the active, antigen-loaded dendritic cells, wherein the second pharmaceutical composition is administered subcutaneously.

17. The method of claim 16 , wherein the concentration of the active, antigen-loaded dendritic cells in the second pharmaceutical composition is at least about 15×10 6 viable cells/ml.

18. The method of claim 16 , wherein the second pharmaceutical composition is administered to the subject in combination with one or more chemotherapeutic agents comprising one or more of doxorubicin, cyclophosphamide, and paclitaxel.

19. The method of claim 3 , further comprising surgically removing breast cancer tissue and/or administering radiation treatment.

Assignees

• Baylor Res Institute

Inventors

• Palucka Anna Karolina
• Banchereau Jacques F
• Roberts Lee

Classifications

• A61K2039/812

  Breast · CPC title

• A61K31/675

  having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate · CPC title

• A61K38/2006

  IL-1 · CPC title

• A61K31/337

  having four-membered rings, e.g. taxol · CPC title

• C12N2501/2304

  Interleukin-4 (IL-4) · CPC title